- Establishment, law & taxes
Package of measures for Startup Location Austria
Austria is an attractive location for startups. Company founders benefit from extensive support services and funding, amongst other advantages. According to the Global Entrepreneurship Monitor 2022, Austria is ranked first in an international comparison when it comes to startup funding.
In order to further promote innovation and the founding of startups, a comprehensive package of measures - the new Startup Package - is currently being subject to a formal evaluation procedure. It brings significant improvements and thus strengthens Austria’s attractiveness for startup founders. The draft legislation stipulates the creation of a new type of corporation. The so-called flexible corporation (German: “Flexible Kapitalgesellschaft” or FlexKapG) targets startups as well as innovative SMEs and leads to simplifications with respect to formalities and written voting or circular resolutions. Furthermore, entrepreneurship is promoted by reducing the minimum share capital to € 10,000 for limited liability companies (GmbHs) and for the FlexKapG.
Another important step is the frequently demanded measure of establishing a legal foundation for employee participation programmes based on corporate and tax law and complemented by tax relief. This is considered to be a crucial labour market initiative to retain highly qualified skilled workers. In this way, selected employees can receive employee stock options in the form of enterprise value shares in addition to their regular salaries. The advantage is that this will not only be offered in line with company law with few formal requirements, but also result in substantial relief with regard to duties and taxes.
- Learn more about startup-founding in Austria
Attractive research and innovation location27. February 2024
ABA’s INVEST in AUSTRIA business area coordinated the handling of 1,354 inquiries on the part of international companies in 2023 and ended up overseeing 496 ongoing business location and expansion projects.
Novartis invests about € 500 million in its Austrian facilities27. February 2024
The investment strengthens the Tyrolean Kundl/Schaftenau campus as a leading biotech location in Europe and helps accelerate the continuous supply of biopharmaceuticals from Austria. The Schaftenau plant is scheduled to be fully operational in the summer of 2024, whereas the Kundl facility will be operational in the autumn of 2025, creating 350 new high-skilled jobs on campus.